Cumberland Pharmaceuticals Inc Financials
This page shows Cumberland Pharmaceuticals Inc (CPIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Cumberland Pharmaceuticals Inc has an operating margin of -17.0%, meaning the company retains $-17 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -24.2% the prior year.
Cumberland Pharmaceuticals Inc's revenue declined 4.3% year-over-year, from $39.6M to $37.9M. This contraction results in a growth score of 16/100.
Cumberland Pharmaceuticals Inc has elevated debt relative to equity (D/E of 2.32), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 25/100, reflecting increased financial risk.
Cumberland Pharmaceuticals Inc's current ratio of 1.15 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 26/100, which could limit financial flexibility.
While Cumberland Pharmaceuticals Inc generated -$612K in operating cash flow, capex of $66K consumed most of it, leaving -$679K in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Cumberland Pharmaceuticals Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Cumberland Pharmaceuticals Inc generates $0.09 in operating cash flow (-$612K OCF vs -$6.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Cumberland Pharmaceuticals Inc earns $-10.6 in operating income for every $1 of interest expense (-$6.4M vs $606K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Cumberland Pharmaceuticals Inc generated $37.9M in revenue in fiscal year 2024. This represents a decrease of 4.3% from the prior year.
Cumberland Pharmaceuticals Inc's EBITDA was -$1.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 66.9% from the prior year.
Cumberland Pharmaceuticals Inc generated -$679K in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 111.7% from the prior year.
Cumberland Pharmaceuticals Inc reported -$6.5M in net income in fiscal year 2024. This represents a decrease of 3.2% from the prior year.
Cumberland Pharmaceuticals Inc earned $-0.46 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 4.5% from the prior year.
Cumberland Pharmaceuticals Inc held $18.0M in cash against $0 in long-term debt as of fiscal year 2024.
Cumberland Pharmaceuticals Inc had 14M shares outstanding in fiscal year 2024. This represents a decrease of 1.2% from the prior year.
Cumberland Pharmaceuticals Inc's gross margin was 82.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 2.1 percentage points from the prior year.
Cumberland Pharmaceuticals Inc's operating margin was -17.0% in fiscal year 2024, reflecting core business profitability. This is up 7.2 percentage points from the prior year.
Cumberland Pharmaceuticals Inc's net profit margin was -17.1% in fiscal year 2024, showing the share of revenue converted to profit. This is down 1.2 percentage points from the prior year.
Cumberland Pharmaceuticals Inc invested $4.8M in research and development in fiscal year 2024. This represents a decrease of 17.4% from the prior year.
Cumberland Pharmaceuticals Inc spent $579K on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 21.8% from the prior year.
Cumberland Pharmaceuticals Inc invested $66K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 76.4% from the prior year.
CPIX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.3M-23.5% | $10.8M-7.5% | $11.7M+12.2% | $10.4M+14.9% | $9.1M-7.7% | $9.8M+15.9% | $8.5M-9.1% | $9.4M |
| Cost of Revenue | $989K-50.8% | $2.0M+41.1% | $1.4M-27.9% | $2.0M+49.4% | $1.3M-22.7% | $1.7M+8.6% | $1.6M+3.0% | $1.5M |
| Gross Profit | $7.3M-17.2% | $8.8M-14.2% | $10.3M+21.6% | $8.5M+9.0% | $7.8M-4.6% | $8.1M+17.6% | $6.9M-11.5% | $7.8M |
| R&D Expenses | $1.3M-14.6% | $1.5M+13.4% | $1.3M+0.2% | $1.3M-1.0% | $1.3M+23.3% | $1.1M-8.6% | $1.2M-8.4% | $1.3M |
| SG&A Expenses | $2.6M-10.5% | $2.9M+16.7% | $2.5M-26.0% | $3.3M+24.3% | $2.7M-3.0% | $2.8M+16.4% | $2.4M-31.1% | $3.4M |
| Operating Income | -$2.0M-162.9% | -$747K-157.9% | $1.3M+170.1% | -$1.8M-8.7% | -$1.7M-65.0% | -$1.0M+45.1% | -$1.9M+69.7% | -$6.2M |
| Interest Expense | $110K+0.1% | $110K-33.1% | $164K-26.6% | $223K+62.5% | $137K+8.7% | $126K+6.6% | $119K-33.7% | $179K |
| Income Tax | $6K0.0% | $6K0.0% | $6K+109.9% | -$57K-598.1% | $11K0.0% | $11K0.0% | $11K-54.2% | $25K |
| Net Income | -$1.9M-162.0% | -$741K-158.9% | $1.3M+166.0% | -$1.9M-23.3% | -$1.5M-42.2% | -$1.1M+44.2% | -$1.9M+69.1% | -$6.3M |
| EPS (Diluted) | $-0.13-160.0% | $-0.05-162.5% | $0.08+157.1% | $-0.14-27.3% | $-0.11-37.5% | $-0.08+42.9% | $-0.14+68.2% | $-0.44 |
CPIX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $65.9M-3.0% | $67.9M-2.9% | $69.9M-7.5% | $75.6M-1.5% | $76.7M-2.3% | $78.5M-3.7% | $81.5M-0.3% | $81.8M |
| Current Assets | $29.9M-4.1% | $31.2M-2.1% | $31.9M-12.6% | $36.5M+3.5% | $35.2M-1.0% | $35.6M-1.7% | $36.2M+1.4% | $35.7M |
| Cash & Equivalents | $15.2M-5.5% | $16.1M+6.5% | $15.1M-15.9% | $18.0M+2.9% | $17.5M+0.7% | $17.3M-6.5% | $18.5M+1.2% | $18.3M |
| Inventory | $2.9M-8.9% | $3.2M-21.4% | $4.1M+2.5% | $4.0M-11.3% | $4.5M+4.8% | $4.3M-0.6% | $4.3M-6.1% | $4.6M |
| Accounts Receivable | $10.4M+1.1% | $10.3M-1.6% | $10.5M-10.4% | $11.7M+3.5% | $11.3M-2.7% | $11.6M+9.1% | $10.6M+9.1% | $9.8M |
| Goodwill | $914K0.0% | $914K0.0% | $914K0.0% | $914K0.0% | $914K0.0% | $914K0.0% | $914K0.0% | $914K |
| Total Liabilities | $40.1M-0.3% | $40.2M-3.3% | $41.6M-21.6% | $53.0M+1.5% | $52.3M-0.4% | $52.5M-3.4% | $54.3M+3.4% | $52.5M |
| Current Liabilities | $24.3M+1.4% | $24.0M-6.1% | $25.5M-19.3% | $31.6M+1.7% | $31.1M+25.6% | $24.8M-6.3% | $26.4M-5.6% | $28.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $26.1M-6.7% | $28.0M-2.3% | $28.7M+25.4% | $22.9M-7.8% | $24.8M-6.0% | $26.3M-4.1% | $27.5M-7.1% | $29.6M |
| Retained Earnings | -$25.4M-8.3% | -$23.5M-3.3% | -$22.7M+5.2% | -$24.0M-8.6% | -$22.1M-7.5% | -$20.5M-5.6% | -$19.4M-11.1% | -$17.5M |
CPIX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $187K-77.8% | $844K-78.4% | $3.9M+104.7% | $1.9M+300.5% | $476K+155.6% | -$856K+60.0% | -$2.1M-305.4% | $1.0M |
| Capital Expenditures | $24K-10.2% | $26K-44.4% | $48K+1986.3% | $2K-85.2% | $15K+114.3% | $7K-82.8% | $42K-14.5% | $49K |
| Free Cash Flow | $163K-80.0% | $817K-78.8% | $3.9M+102.4% | $1.9M+313.4% | $460K+153.3% | -$863K+60.4% | -$2.2M-319.7% | $991K |
| Investing Cash Flow | -$691K-341.7% | $286K+123.3% | -$1.2M-4481.2% | -$27K-114.1% | $190K+505.2% | -$47K+19.6% | -$58K-122.3% | $261K |
| Financing Cash Flow | -$387K-156.6% | -$151K+97.3% | -$5.5M-300.9% | -$1.4M-156.8% | -$537K-73.4% | -$310K-112.8% | $2.4M+262.8% | -$1.5M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $10K+45.6% | $7K-97.1% | $246K+149.9% | $98K-0.4% | $99K-26.4% | $134K-45.8% | $248K+31.0% | $189K |
CPIX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.1%+6.6pp | 81.4%-6.4pp | 87.8%+6.8pp | 81.1%-4.4pp | 85.4%+2.8pp | 82.6%+1.2pp | 81.5%-2.2pp | 83.6% |
| Operating Margin | -23.7%-16.8pp | -6.9%-17.9pp | 11.0%+28.7pp | -17.6%+1.0pp | -18.6%-8.2pp | -10.4%+11.6pp | -22.0%+44.1pp | -66.1% |
| Net Margin | -23.4%-16.6pp | -6.8%-17.6pp | 10.7%+29.0pp | -18.2%-1.3pp | -17.0%-6.0pp | -11.0%+11.9pp | -22.9%+44.4pp | -67.3% |
| Return on Equity | N/A | N/A | 4.4% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -2.9%-1.9pp | -1.1%-2.9pp | 1.8%+4.3pp | -2.5%-0.5pp | -2.0%-0.6pp | -1.4%+1.0pp | -2.4%+5.3pp | -7.7% |
| Current Ratio | 1.23-0.1 | 1.30+0.1 | 1.25+0.1 | 1.15+0.0 | 1.13-0.3 | 1.44+0.1 | 1.37+0.1 | 1.28 |
| Debt-to-Equity | 1.54+0.1 | 1.44-0.0 | 1.45-0.9 | 2.32+0.2 | 2.11+0.1 | 1.99+0.0 | 1.98+0.2 | 1.77 |
| FCF Margin | 2.0%-5.6pp | 7.5%-25.3pp | 32.9%+14.6pp | 18.2%+13.2pp | 5.1%+13.8pp | -8.8%+16.9pp | -25.6%-36.2pp | 10.6% |
Similar Companies
Frequently Asked Questions
What is Cumberland Pharmaceuticals Inc's annual revenue?
Cumberland Pharmaceuticals Inc (CPIX) reported $37.9M in total revenue for fiscal year 2024. This represents a -4.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cumberland Pharmaceuticals Inc's revenue growing?
Cumberland Pharmaceuticals Inc (CPIX) revenue declined by 4.3% year-over-year, from $39.6M to $37.9M in fiscal year 2024.
Is Cumberland Pharmaceuticals Inc profitable?
No, Cumberland Pharmaceuticals Inc (CPIX) reported a net income of -$6.5M in fiscal year 2024, with a net profit margin of -17.1%.
What is Cumberland Pharmaceuticals Inc's earnings per share (EPS)?
Cumberland Pharmaceuticals Inc (CPIX) reported diluted earnings per share of $-0.46 for fiscal year 2024. This represents a -4.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Cumberland Pharmaceuticals Inc's EBITDA?
Cumberland Pharmaceuticals Inc (CPIX) had EBITDA of -$1.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cumberland Pharmaceuticals Inc's gross margin?
Cumberland Pharmaceuticals Inc (CPIX) had a gross margin of 82.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cumberland Pharmaceuticals Inc's operating margin?
Cumberland Pharmaceuticals Inc (CPIX) had an operating margin of -17.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Cumberland Pharmaceuticals Inc's net profit margin?
Cumberland Pharmaceuticals Inc (CPIX) had a net profit margin of -17.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Cumberland Pharmaceuticals Inc's free cash flow?
Cumberland Pharmaceuticals Inc (CPIX) generated -$679K in free cash flow during fiscal year 2024. This represents a -111.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cumberland Pharmaceuticals Inc's operating cash flow?
Cumberland Pharmaceuticals Inc (CPIX) generated -$612K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Cumberland Pharmaceuticals Inc's total assets?
Cumberland Pharmaceuticals Inc (CPIX) had $75.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Cumberland Pharmaceuticals Inc's capital expenditures?
Cumberland Pharmaceuticals Inc (CPIX) invested $66K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Cumberland Pharmaceuticals Inc spend on research and development?
Cumberland Pharmaceuticals Inc (CPIX) invested $4.8M in research and development during fiscal year 2024.
Does Cumberland Pharmaceuticals Inc buy back shares?
Yes, Cumberland Pharmaceuticals Inc (CPIX) spent $579K on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Cumberland Pharmaceuticals Inc have outstanding?
Cumberland Pharmaceuticals Inc (CPIX) had 14M shares outstanding as of fiscal year 2024.
What is Cumberland Pharmaceuticals Inc's current ratio?
Cumberland Pharmaceuticals Inc (CPIX) had a current ratio of 1.15 as of fiscal year 2024, which is considered adequate.
What is Cumberland Pharmaceuticals Inc's debt-to-equity ratio?
Cumberland Pharmaceuticals Inc (CPIX) had a debt-to-equity ratio of 2.32 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cumberland Pharmaceuticals Inc's return on assets (ROA)?
Cumberland Pharmaceuticals Inc (CPIX) had a return on assets of -8.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Cumberland Pharmaceuticals Inc's cash runway?
Based on fiscal year 2024 data, Cumberland Pharmaceuticals Inc (CPIX) had $18.0M in cash against an annual operating cash burn of $612K. This gives an estimated cash runway of approximately 352 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cumberland Pharmaceuticals Inc's Piotroski F-Score?
Cumberland Pharmaceuticals Inc (CPIX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cumberland Pharmaceuticals Inc's earnings high quality?
Cumberland Pharmaceuticals Inc (CPIX) has an earnings quality ratio of 0.09x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cumberland Pharmaceuticals Inc cover its interest payments?
Cumberland Pharmaceuticals Inc (CPIX) has an interest coverage ratio of -10.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Cumberland Pharmaceuticals Inc?
Cumberland Pharmaceuticals Inc (CPIX) scores 14 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.